Tempest Therapeutics Inc., a clinical-stage biotechnology company developing a broad portfolio of first-in-class immunomodulatory small molecules targeting diverse cancers, today announced that the first patient has been dosed with TPST-1120 in a Phase I/Ib trial to...
Approval allows Zai Lab to enroll patients in a global Phase 3 clinical trial in collaboration with Entasis Therapeutics More than 200,000 cases of A. baumannii infections in China annually – Approximately 60% are carbapenem-resistant – High mortality rate...
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that it has enrolled the first patient in a pivotal Phase 3 clinical trial of fostamatinib disodium hexahydrate (fostamatinib) in warm antibody autoimmune hemolytic anemia (AIHA). The clinical trial protocol...
National Cancer Institute (NCI) Study Designed to Investigate Zotiraciclib in Combination with Temozolomide (TMZ) for the Treatment of Recurrent Malignant Gliomas Adastra Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of proprietary...
ImaginAb Inc., a clinical stage immuno-oncology imaging company, announces it has enrolled its first patient for the Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at City of Hope in Los Angeles County. City of Hope is a world-renowned...
Pfizer Inc. (NYSE: PFE) announced today positive top-line results from a Phase 3 pivotal study (B7451012) evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib (PF-04965842), in patients aged 12 and older with...
Email
Text